In the multivariate analysis, the prognosis of iPFS and OS in all advanced NSCLC patients with de novo BM were not correlated with the EGFR mutation subtype (HR=0.92 [95%CI (0.75-1.13)], P=0.428). Here, EGFR is linked to non-small cell lung carcinoma.